Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastro-Retentive Memantine HCl Capsules in Healthy Subjects
NCT03468543Phase 1Terminated
- Sponsor
- Lyndra Therapeutics
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of memantine in Alzheimer's disease (AD) (3 cohorts), sponsored by Lyndra Therapeutics. Primary endpoint: Gastric Retention by Magnetic Resonance Imaging (MRI) at 7 Days. Started Jul 2017; status: terminated.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03468543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468543.